The Mitochondrial Electron Transport Chain: Powerhouse of Cellular Energy

The Mitochondrial Electron Transport Chain (ETC) is a crucial series of protein complexes embedded in the inner mitochondrial membrane. This intricate system orchestrates a sequence of redox reactions, skillfully channeling energy to establish an electrochemical gradient. This gradient is the driving force behind ATP synthase, the molecular machinery responsible for generating the cell’s primary energy currency, ATP, in a process known as oxidative phosphorylation. This vital process is central to cellular respiration within mitochondria and also plays a key role in photosynthesis within chloroplasts. In cellular respiration, the ETC harnesses electrons derived from the breakdown of nutrient-rich organic molecules to liberate energy. Conversely, in photosynthesis, light energy excites electrons, initiating their entry into the chain, and the energy released is then cleverly utilized to synthesize carbohydrates.

Delving into the Fundamentals of the Electron Transport Chain

Aerobic cellular respiration, the process of energy extraction from glucose in the presence of oxygen, unfolds in three distinct stages: glycolysis, the citric acid (Krebs) cycle, and oxidative phosphorylation. Glycolysis, the initial step, occurs in the cytoplasm and breaks down glucose into two pyruvate molecules, yielding a small net gain of ATP and the electron carrier NADH. Pyruvate then transitions into the mitochondria, where it undergoes oxidative decarboxylation to form acetyl-CoA, releasing carbon dioxide and generating another molecule of NADH. Acetyl-CoA fuels the citric acid cycle, a cyclical metabolic pathway within the mitochondrial matrix that further oxidizes carbon, producing carbon dioxide, more NADH and FADH2 (another electron carrier), and a small amount of ATP. The grand finale, oxidative phosphorylation, is where the electron transport chain takes center stage. The NADH and FADH2 generated in the preceding stages deliver their high-energy electrons to the ETC, powering the synthesis of a substantial amount of ATP and culminating in the formation of water.

Oxidative phosphorylation is a two-pronged process encompassing the electron transport chain (ETC) and chemiosmosis. The ETC is an assembly of protein complexes and mobile electron carriers nestled within the inner mitochondrial membrane. Electrons journey through this chain in a series of redox reactions, progressively stepping down in energy levels. This controlled energy release is not wasted; instead, it is skillfully harnessed to pump protons (H+) from the mitochondrial matrix into the intermembrane space, establishing a proton gradient. Chemiosmosis then capitalizes on this proton gradient. The potential energy stored in the gradient is tapped by ATP synthase, a remarkable enzyme that acts as a channel for protons to flow back down their concentration gradient into the matrix. This controlled flow of protons provides the energy needed for ATP synthase to phosphorylate ADP, generating large quantities of ATP.

Photosynthesis, the remarkable process by which plants and other organisms convert light energy into chemical energy, also relies on an electron transport chain. The light-dependent reactions of photosynthesis capture light energy and utilize water to produce ATP, NADPH (another electron carrier similar to NADH), and oxygen (O2). Crucially, an electron transport chain plays a vital role in establishing the proton gradient necessary for ATP synthesis during these light-dependent reactions. The ATP and NADPH generated are then utilized in the light-independent reactions (Calvin cycle) to fix carbon dioxide and synthesize sugars, the energy-rich molecules that sustain life.

The Electron Transport Chain at the Cellular Level

Within the electron transport chain (ETC), electrons embark on a journey through a sequence of protein complexes, each strategically positioned to have a progressively higher reduction potential. This stepwise increase in reduction potential ensures that electron transfer is energetically favorable, driving the process forward and releasing energy along the way. A significant portion of this released energy is carefully captured and utilized to actively pump protons (H+) from the mitochondrial matrix into the intermembrane space. This proton pumping action is the key to creating the proton gradient, also known as the electrochemical gradient. This gradient manifests as a difference in both pH (acidity) and electrical charge across the inner mitochondrial membrane. The intermembrane space becomes more acidic (higher H+ concentration, lower pH) and positively charged relative to the mitochondrial matrix, which becomes more alkaline (lower H+ concentration, higher pH) and negatively charged. The major protein complexes of the ETC, in their general functional order, are Complex I, Complex II, Coenzyme Q, Complex III, Cytochrome c, and Complex IV.

• Complex I (NADH dehydrogenase): This entry point to the ETC accepts electrons from NADH, which is generated by glycolysis, the citric acid cycle, and fatty acid oxidation. Complex I catalyzes the oxidation of NADH, transferring two electrons to ubiquinone (Coenzyme Q) and simultaneously pumping four protons across the inner mitochondrial membrane from the matrix to the intermembrane space.

  • NADH + H+ + CoQ -> NAD+ + CoQH2 (Protons pumped across membrane)

• Complex II (Succinate dehydrogenase): Also known as succinate dehydrogenase, Complex II provides a second entry point for electrons into the ETC. It accepts electrons from succinate, an intermediate in the citric acid cycle. Complex II catalyzes the oxidation of succinate to fumarate. In this process, two electrons are transferred from succinate to FAD (flavin adenine dinucleotide), a prosthetic group within Complex II. FADH2, the reduced form of FAD, then passes these electrons, via iron-sulfur (Fe-S) clusters within the complex, to coenzyme Q. It is important to note that, unlike Complex I, Complex II does not directly pump protons across the inner mitochondrial membrane. Consequently, the pathway involving Complex II yields less ATP compared to the pathway involving Complex I.

  • Succinate + FAD -> Fumarate + FADH2
  • FADH2 + CoQ -> FAD + CoQH2

• Coenzyme Q (Ubiquinone): Coenzyme Q, often abbreviated as CoQ or Q, also known as ubiquinone, is a small, mobile, lipid-soluble molecule. It consists of a quinone ring structure attached to a long hydrophobic isoprenoid tail, which allows it to diffuse freely within the inner mitochondrial membrane. Coenzyme Q serves as a crucial electron carrier, accepting electrons from both Complex I and Complex II and delivering them to Complex III. Coenzyme Q can exist in three redox states: ubiquinone (oxidized form), semiquinone (partially reduced radical form, CoQH•), and ubiquinol (fully reduced form, CoQH2). The Q cycle, described below under Complex III, details the intricate mechanism of CoQ reduction and oxidation within Complex III.

• Complex III (Cytochrome bc1 complex or Coenzyme Q-cytochrome c reductase): Complex III receives electrons from ubiquinol (CoQH2). It catalyzes the oxidation of ubiquinol and the transfer of electrons to cytochrome c, another mobile electron carrier. Complex III operates through a sophisticated mechanism known as the Q cycle. In the Q cycle, for every two electrons transferred to cytochrome c, four protons are pumped across the inner mitochondrial membrane: two protons are released into the intermembrane space from ubiquinol oxidation, and two protons are taken up from the matrix in the reduction of ubiquinone.

• Cytochrome c: Cytochrome c is a small, soluble protein located in the intermembrane space of the mitochondria. It acts as a mobile electron carrier, ferrying electrons from Complex III to Complex IV. Cytochrome c is a heme-containing protein, and it undergoes oxidation and reduction as it shuttles electrons between complexes.

• Complex IV (Cytochrome c oxidase): Complex IV, also known as cytochrome c oxidase, is the final protein complex in the electron transport chain. It receives electrons from cytochrome c and catalyzes the final redox reaction: the reduction of molecular oxygen (O2) to water (H2O). This reaction is highly exergonic and provides the energy to pump protons across the inner mitochondrial membrane. For every four electrons passed through Complex IV, four protons are pumped from the matrix to the intermembrane space, and two molecules of water are formed. Oxygen serves as the terminal electron acceptor in the electron transport chain, without which the entire chain would grind to a halt.

  • 2 Cytochrome c (reduced) + 4 H+ (matrix) + O2 -> 2 Cytochrome c (oxidized) + 2 H+ (intermembrane space) + 2 H2O

• ATP synthase (Complex V): Although not directly involved in electron transport, ATP synthase, also called Complex V, is functionally linked to the ETC. It harnesses the proton gradient generated by Complexes I, III, and IV to synthesize ATP. ATP synthase is a remarkable molecular machine composed of two main subunits: F0 and F1. The F0 subunit is embedded within the inner mitochondrial membrane and forms a channel for protons to flow down their electrochemical gradient from the intermembrane space back into the matrix. The flow of protons through F0 drives the rotation of a part of the F0 subunit, which, in turn, mechanically rotates the F1 subunit. The F1 subunit, located in the mitochondrial matrix, contains the catalytic sites for ATP synthesis. The mechanical rotation of F1 induces conformational changes in its catalytic subunits, driving the binding of ADP and inorganic phosphate (Pi), the phosphorylation of ADP to ATP, and the release of ATP. It is estimated that approximately 4 protons must pass through ATP synthase for each molecule of ATP synthesized. Interestingly, ATP synthase can also operate in reverse. Under conditions of high ATP concentration and a weak proton gradient, ATP hydrolysis can drive proton pumping from the matrix to the intermembrane space, consuming ATP to build a hydrogen gradient, a function observed in some bacteria.

The Electron Transport Chain at the Molecular Level

Nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD) are key electron carriers that fuel the electron transport chain. NAD+ exists in two forms: the oxidized form NAD+ and the reduced form NADH. It is a dinucleotide composed of two nucleotides linked through their phosphate groups. One nucleotide contains an adenine base, and the other contains nicotinamide, a derivative of vitamin B3 (niacin). In metabolic redox reactions, NAD+ acts as an oxidizing agent, accepting two electrons and a proton to become NADH, as depicted in Reaction 1.

• Reaction 1: RH2 + NAD+ -> R + H+ + NADH

In this reaction, RH2 represents a substrate being oxidized (e.g., a sugar molecule), and R is the oxidized product.

NADH delivers its electrons to Complex I of the ETC. As electrons are transferred down the chain from Complex I through Complex IV, a total of approximately 10 protons are pumped across the inner mitochondrial membrane (4 from Complex I, 4 from Complex III, and 2 from Complex IV). Since ATP synthase synthesizes approximately 1 ATP for every 4 protons that flow through it, the oxidation of one molecule of NADH is theoretically estimated to yield around 2.5 molecules of ATP (some sources may round this value up to 3 ATP). When NADH is oxidized back to NAD+, it releases a proton (H+) and two electrons, as shown in Reaction 2.

• Reaction 2: NADH -> H+ + NAD+ + 2 e-

Flavin adenine dinucleotide (FAD), like NAD+, is another crucial redox cofactor. FAD also exists in oxidized and reduced forms, as well as a semiquinone intermediate. The fully oxidized form is FAD (quinone form), and the fully reduced form is FADH2 (hydroquinone form). FAD is composed of an adenine nucleotide and flavin mononucleotide (FMN), linked by phosphate groups. FMN is derived in part from vitamin B2 (riboflavin). FAD contains a stable aromatic ring system, which is lost upon reduction to FADH2. The oxidation of FADH2 back to FAD, as seen in Reaction 3, restores the aromaticity and releases energy. This makes FAD a potent oxidizing agent, possessing an even more positive reduction potential than NAD+. FADH2 feeds electrons into the ETC at Complex II. The electrons from FADH2 travel through Complexes II, III, and IV, resulting in the pumping of approximately 6 protons (4 from Complex III and 2 from Complex IV). Therefore, the oxidation of one molecule of FADH2 is estimated to produce around 1.5 molecules of ATP (6 protons / 4 protons per ATP; some sources may round this value up to 2 ATP).

• Reaction 3: FADH2 -> FAD + 2 H+ + 2 e-

Beyond its role in the ETC, FAD participates in numerous other metabolic pathways, including DNA repair (MTHF repair of UV damage), fatty acid beta-oxidation (acyl-CoA dehydrogenase), and the synthesis of other essential coenzymes (CoA, CoQ, heme).

Clinical Significance of the Electron Transport Chain

Dysfunction of the mitochondrial electron transport chain is implicated in a wide range of human diseases, highlighting its critical importance for health.

Uncoupling Agents

Uncoupling agents are substances that disrupt the tight coupling between the electron transport chain and ATP synthesis by ATP synthase. These agents effectively dissociate the proton gradient from ATP production, allowing the ETC to continue functioning and consuming oxygen, but preventing the generation of ATP. Many uncoupling agents are lipophilic weak acids that can insert into the inner mitochondrial membrane. They facilitate proton leakage across the membrane, bypassing ATP synthase. This proton leak diminishes the electrochemical gradient, and the energy stored in the gradient is released as heat rather than being harnessed to synthesize ATP.

As ATP production plummets, the cell is effectively starved of energy. In response, the ETC becomes hyperactive, attempting to compensate for the energy deficit by shuttling more and more electrons in a futile attempt to drive ATP synthesis. The electron transport chain inherently generates heat as electrons are transferred between carriers. This heightened ETC activity significantly increases heat production, potentially leading to a dangerous elevation in body temperature (hyperthermia). Furthermore, the cellular energy crisis can trigger a metabolic shift towards anaerobic metabolism, even in the presence of oxygen. Cells may resort to fermentation to generate ATP, resulting in the accumulation of lactic acid and potentially causing type B lactic acidosis in affected individuals.

Examples of uncoupling agents include:

• Aspirin (Salicylic Acid): At high doses, aspirin can act as an uncoupling agent.
• Thermogenin (UCP1): Thermogenin is a naturally occurring uncoupling protein found in the mitochondria of brown adipose tissue (brown fat). It plays a crucial role in non-shivering thermogenesis, allowing brown fat to generate heat instead of ATP, particularly important for maintaining body temperature in newborns and hibernating animals.

Oxidative Phosphorylation Inhibitors

A variety of toxins and drugs can specifically inhibit components of the electron transport chain or ATP synthase, effectively blocking oxidative phosphorylation and cellular ATP production. These oxidative phosphorylation inhibitors can have severe consequences, leading to cellular energy depletion and potentially cell death.

Examples of ETC inhibitors include:

• Rotenone (and some barbiturates): Rotenone, a natural insecticide, inhibits Complex I by blocking the binding of coenzyme Q.
• Carboxin: Carboxin, a fungicide (no longer widely used), also inhibits Complex II at the coenzyme Q binding site.
• Doxorubicin: Doxorubicin, an anticancer drug, is thought to interfere with coenzyme Q function, although the exact mechanism is still under investigation.
• Antimycin A: Antimycin A, a piscicide, inhibits Complex III (cytochrome c reductase) by binding to the Qi binding site. This prevents ubiquinone from binding and accepting electrons, disrupting the Q cycle and blocking electron flow.
• Carbon Monoxide (CO): Carbon monoxide is a potent inhibitor of Complex IV (cytochrome c oxidase). CO binds to the heme iron in cytochrome oxidase with high affinity, preventing oxygen binding and blocking the final step of electron transport. Carbon monoxide poisoning leads to tissue hypoxia, as cells are unable to utilize oxygen for ATP production. Symptoms of CO poisoning can include headache, dizziness, nausea, and in severe cases, coma and death. Treatment involves administering high concentrations of oxygen and, in severe cases, hyperbaric oxygen therapy.
• Cyanide (CN-): Cyanide is another highly toxic inhibitor of Complex IV (cytochrome c oxidase). Cyanide binds to the heme iron in cytochrome oxidase, similar to carbon monoxide, blocking oxygen binding and electron transport. Cyanide poisoning also results in tissue hypoxia. Symptoms can resemble CO poisoning but may also include a characteristic almond odor on the breath. Cyanide exposure can result from house fires, jewelry cleaning solutions, industrial processes, and even ingestion of certain fruit seeds (e.g., apricot, peach, apple seeds). Treatment for cyanide poisoning may involve nitrites to induce methemoglobinemia (methemoglobin binds cyanide), methylene blue to reduce methemoglobin back to hemoglobin, hydroxocobalamin (vitamin B12 precursor), and thiosulfate.
• Oligomycin: Oligomycin is an antibiotic that inhibits ATP synthase (Complex V). Oligomycin binds to the F0 subunit of ATP synthase, blocking the proton channel and preventing proton flow through the enzyme. This directly inhibits ATP synthesis.

Electron Transport Chain Diagram

This diagram illustrates the key components of the electron transport chain, including Complexes I-IV, Coenzyme Q, Cytochrome c, and ATP synthase (Complex V). It highlights the flow of electrons, proton pumping, and ATP synthesis in the mitochondria. Illustration by Emma Gregory.

References

1.Lencina AM, Franza T, Sullivan MJ, Ulett GC, Ipe DS, Gaudu P, Gennis RB, Schurig-Briccio LA. Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target. mBio. 2018 Jul 03;9(4) [PMC free article: PMC6030563] [PubMed: 29970468]

2.Hirst J. Towards the molecular mechanism of respiratory complex I. Biochem J. 2009 Dec 23;425(2):327-39. [PubMed: 20025615]

3.Sazanov LA, Hinchliffe P. Structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus. Science. 2006 Mar 10;311(5766):1430-6. [PubMed: 16469879]

4.Hirst J. Energy transduction by respiratory complex I–an evaluation of current knowledge. Biochem Soc Trans. 2005 Jun;33(Pt 3):525-9. [PubMed: 15916556]

5.Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Léger C, Byrne B, Cecchini G, Iwata S. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science. 2003 Jan 31;299(5607):700-4. [PubMed: 12560550]

6.Horsefield R, Iwata S, Byrne B. Complex II from a structural perspective. Curr Protein Pept Sci. 2004 Apr;5(2):107-18. [PubMed: 15078221]

7.Geertman JM, van Maris AJ, van Dijken JP, Pronk JT. Physiological and genetic engineering of cytosolic redox metabolism in Saccharomyces cerevisiae for improved glycerol production. Metab Eng. 2006 Nov;8(6):532-42. [PubMed: 16891140]

8.Thorpe C, Kim JJ. Structure and mechanism of action of the acyl-CoA dehydrogenases. FASEB J. 1995 Jun;9(9):718-25. [PubMed: 7601336]

9.Sun C, Benlekbir S, Venkatakrishnan P, Wang Y, Hong S, Hosler J, Tajkhorshid E, Rubinstein JL, Gennis RB. Structure of the alternative complex III in a supercomplex with cytochrome oxidase. Nature. 2018 May;557(7703):123-126. [PMC free article: PMC6004266] [PubMed: 29695868]

10.Iwata S, Lee JW, Okada K, Lee JK, Iwata M, Rasmussen B, Link TA, Ramaswamy S, Jap BK. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science. 1998 Jul 03;281(5373):64-71. [PubMed: 9651245]

11.Trumpower BL. The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc1 complex. J Biol Chem. 1990 Jul 15;265(20):11409-12. [PubMed: 2164001]

12.Hunte C, Palsdottir H, Trumpower BL. Protonmotive pathways and mechanisms in the cytochrome bc1 complex. FEBS Lett. 2003 Jun 12;545(1):39-46. [PubMed: 12788490]

13.Calhoun MW, Thomas JW, Gennis RB. The cytochrome oxidase superfamily of redox-driven proton pumps. Trends Biochem Sci. 1994 Aug;19(8):325-30. [PubMed: 7940677]

14.Schmidt-Rohr K. Oxygen Is the High-Energy Molecule Powering Complex Multicellular Life: Fundamental Corrections to Traditional Bioenergetics. ACS Omega. 2020 Feb 11;5(5):2221-2233. [PMC free article: PMC7016920] [PubMed: 32064383]

15.Lovero D, Giordano L, Marsano RM, Sanchez-Martinez A, Boukhatmi H, Drechsler M, Oliva M, Whitworth AJ, Porcelli D, Caggese C. Characterization of Drosophila ATPsynC mutants as a new model of mitochondrial ATP synthase disorders. PLoS One. 2018;13(8):e0201811. [PMC free article: PMC6086398] [PubMed: 30096161]

16.Okuno D, Iino R, Noji H. Rotation and structure of FoF1-ATP synthase. J Biochem. 2011 Jun;149(6):655-64. [PubMed: 21524994]

17.Junge W, Nelson N. ATP synthase. Annu Rev Biochem. 2015;84:631-57. [PubMed: 25839341]

18.Hinkle PC. P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta. 2005 Jan 07;1706(1-2):1-11. [PubMed: 15620362]

19.Barrett MA, Zheng S, Roshankar G, Alsop RJ, Belanger RK, Huynh C, Kučerka N, Rheinstädter MC. Interaction of aspirin (acetylsalicylic acid) with lipid membranes. PLoS One. 2012;7(4):e34357. [PMC free article: PMC3328472] [PubMed: 22529913]

20.Warrick BJ, King A, Smolinske S, Thomas R, Aaron C. A 29-year analysis of acute peak salicylate concentrations in fatalities reported to United States poison centers. Clin Toxicol (Phila). 2018 Sep;56(9):846-851. [PubMed: 29431532]

21.Cinti S. The adipose organ. Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):9-15. [PubMed: 15936182]

22.Enerbäck S. The origins of brown adipose tissue. N Engl J Med. 2009 May 07;360(19):2021-3. [PubMed: 19420373]

23.Zhou W, Faraldo-Gómez JD. Membrane plasticity facilitates recognition of the inhibitor oligomycin by the mitochondrial ATP synthase rotor. Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):789-796. [PMC free article: PMC6176861] [PubMed: 29630891]

24.Kamalian L, Douglas O, Jolly CE, Snoeys J, Simic D, Monshouwer M, Williams DP, Kevin Park B, Chadwick AE. The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity. Toxicol In Vitro. 2018 Dec;53:136-147. [PubMed: 30096366]

25.Wood DM, Alsahaf H, Streete P, Dargan PI, Jones AL. Fatality after deliberate ingestion of the pesticide rotenone: a case report. Crit Care. 2005 Jun;9(3):R280-4. [PMC free article: PMC1175899] [PubMed: 15987402]

26.Lupescu A, Jilani K, Zbidah M, Lang F. Induction of apoptotic erythrocyte death by rotenone. Toxicology. 2012 Oct 28;300(3):132-7. [PubMed: 22727881]

27.Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 2003 Sep;93(3):105-15. [PubMed: 12969434]

28.Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med. 2009 Mar 19;360(12):1217-25. [PubMed: 19297574]

29.Sato K, Tamaki K, Hattori H, Moore CM, Tsutsumi H, Okajima H, Katsumata Y. Determination of total hemoglobin in forensic blood samples with special reference to carboxyhemoglobin analysis. Forensic Sci Int. 1990 Nov;48(1):89-96. [PubMed: 2279722]

30.Barker SJ, Tremper KK. The effect of carbon monoxide inhalation on pulse oximetry and transcutaneous PO2. Anesthesiology. 1987 May;66(5):677-9. [PubMed: 3578881]

31.Raub JA, Mathieu-Nolf M, Hampson NB, Thom SR. Carbon monoxide poisoning–a public health perspective. Toxicology. 2000 Apr 07;145(1):1-14. [PubMed: 10771127]

32.Jensen P, Wilson MT, Aasa R, Malmström BG. Cyanide inhibition of cytochrome c oxidase. A rapid-freeze e.p.r. investigation. Biochem J. 1984 Dec 15;224(3):829-37. [PMC free article: PMC1144519] [PubMed: 6098268]

33.Shchepina LA, Pletjushkina OY, Avetisyan AV, Bakeeva LE, Fetisova EK, Izyumov DS, Saprunova VB, Vyssokikh MY, Chernyak BV, Skulachev VP. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene. 2002 Nov 21;21(53):8149-57. [PubMed: 12444550]

Disclosure: Maria Ahmad declares no relevant financial relationships with ineligible companies.

Disclosure: Adam Wolberg declares no relevant financial relationships with ineligible companies.

Disclosure: Chadi Kahwaji declares no relevant financial relationships with ineligible companies.